Procyon Advisors LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Procyon Advisors LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,473 shares of the biopharmaceutical company’s stock after purchasing an additional 268 shares during the period. Procyon Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $3,343,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. Cardinal Capital Management increased its holdings in Regeneron Pharmaceuticals by 3.8% during the first quarter. Cardinal Capital Management now owns 7,774 shares of the biopharmaceutical company’s stock worth $7,482,000 after buying an additional 284 shares during the last quarter. Janiczek Wealth Management LLC increased its holdings in Regeneron Pharmaceuticals by 20.1% during the first quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 37 shares during the last quarter. Signet Financial Management LLC increased its holdings in Regeneron Pharmaceuticals by 2.0% during the first quarter. Signet Financial Management LLC now owns 4,020 shares of the biopharmaceutical company’s stock worth $3,870,000 after buying an additional 78 shares during the last quarter. Wealthcare Advisory Partners LLC increased its holdings in Regeneron Pharmaceuticals by 14.4% during the first quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 37 shares during the last quarter. Finally, West Paces Advisors Inc. increased its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $18.30 during mid-day trading on Thursday, hitting $1,050.86. 507,676 shares of the company traded hands, compared to its average volume of 478,032. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $1,081.17. The stock has a market cap of $115.79 billion, a price-to-earnings ratio of 31.17, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a fifty day moving average price of $978.05 and a 200-day moving average price of $948.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Leonard S. Schleifer sold 25,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at $399,729,850. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,971 shares of company stock valued at $61,217,654. 7.48% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on REGN shares. Argus increased their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday. TD Cowen increased their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 target price for the company. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.91.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.